Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3084121 | 0.88 | CYP3A4 (0.50) | PTGDR2SMN1; SMN2ALDH1A1GABRA1GABRB1 | |
| SCHEMBL669576 | 0.87 | ALDH1A1 (0.54) | SMN1; SMN2ALDH1A1GABRA1GABRB1GABRA3 | |
| SCHEMBL2723239 | 0.87 | ALDH1A1 (0.56) | PTGDR2SMN1; SMN2ALDH1A1TSHRHPGD | |
| SCHEMBL1546455 | 0.87 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1GABRA1GABRB1GABRA3 | |
| SCHEMBL30318000 | 0.87 | ALDH1A1 (0.46) | PTGDR2SMN1; SMN2ALDH1A1GABRA1GABRB1 | |
| SCHEMBL8176195 | 0.87 | ALDH1A1 (0.46) | PTGDR2SMN1; SMN2ALDH1A1GABRA1GABRB1 | |
| SCHEMBL3388835 | 0.85 | TSHR (0.62) | PTGDR2SMN1; SMN2TSHRHPGDNPSR1 | |
| SCHEMBL15994629 | 0.84 | L3MBTL1 (0.54) | PTGDR2ALDH1A1TSHRL3MBTL1LMNA | |
| SCHEMBL14279020 | 0.83 | TSHR (0.52) | SMN1; SMN2ALDH1A1TSHRHPGDRXFP1 | |
| SCHEMBL13064184 | 0.83 | PTGDR2 (0.71) | PTGDR2SMN1; SMN2TSHRHPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776976-B2 | Triazolone compounds and uses thereof | INCEPTION 2, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776976-B2 | Triazolone compounds and uses thereof | INCEPTION 2, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776976-B2 | Triazolone compounds and uses thereof | INCEPTION 2, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| EP-2822931-B1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION 2 INC (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2822931-B1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION 2 INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9505728-B2 | Triazolone compounds and uses thereof | INCEPTION 2, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505728-B2 | Triazolone compounds and uses thereof | INCEPTION 2, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505728-B2 | Triazolone compounds and uses thereof | INCEPTION 2, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| EP-3041826-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | Inception 2, Inc. (US) | 2016-07-13 | — | — | EP | disclosed |
| US-20160194292-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20150080412-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION 2, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080412-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION 2, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| WO-2015035059-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION 2, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| WO-2015035059-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION 2, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| EP-2822931-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | Inception 2, Inc. (US) | 2015-01-14 | — | — | EP | disclosed |
| WO-2013134562-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION 2, INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| WO-2013134562-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION 2, INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| EP-1912970-A2 | ACYLTRYPTOPHANOLS FOR FERTILITY CONTROL | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-04-23 | — | — | EP | disclosed |
| US-20070060573-A1 | Acyltryptophanols | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-15 | — | — | US | disclosed |
| WO-2007017289-A2 | ACYLTRYPTOPHANOLS FOR FERTILITY CONTROL | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080412-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | PPARA, PPARG, PPARD | PTGDR2 753/4885SMN1; SMN2 2827/4885ALDH1A1 673/4885 |
| US-20160194292-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | PPARA, PPARD, PPARG | PTGDR2 308/4885SMN1; SMN2 2965/4885ALDH1A1 497/4885 |
| US-20070060573-A1 | Acyltryptophanols | FSHR, NPY1R, NPY2R | PTGDR2 280/4885SMN1; SMN2 3867/4885ALDH1A1 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.